Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET.
Shinotoh
H
H
Department of Neurology, School of Medicine, Chiba University, Japan.
Hirayama
K
K
Tateno
Y
Y
D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000493:pharmacokinetics; D002531:Cerebellum / Q000000981:diagnostic imaging / Q000503:physiopathology; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000503:physiopathology; D004292:Dominance, Cerebral / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000502:physiology*; D009434:Neural Pathways / Q000000981:diagnostic imaging / Q000503:physiopathology; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000503:physiopathology; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D013378:Substantia Nigra / Q000000981:diagnostic imaging* / Q000503:physiopathology; D014055:Tomography, Emission-Computed
D001552:Benzazepines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D004298:Dopamine